Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...